\
&
Contact us
This was 2 years ago
LocationBrussels, Belgium
The European Commission’s Directorate-General Research & Innovation (DG R&I) organises this event which is part of the awareness raising campaign on knowledge valorisation co-organised by the European Commission with EU Member States. The campaign aims to inform the research and innovation actors about the recent Council Recommendation on the Guiding principles for knowledge valorisation and the Commission Recommendations on the Code of practice on the management of intellectual assets and the Code of practice on standardisation.
The various sessions at the conference will facilitate exchange of views and open discussion concerning the most successful practices to be translated in the R&I environment. Practical insights from the projects will be shared enabling collaborative networking opportunities.
Programme in brief
The full programme and registration form are available in the event announcement on the European Commission DG R&I website
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.